Pavan K Yadav, Saurabh Verma, Divya Chauhan, Pooja Yadav, Amrendra K Tiwari, Ravi Saklani, Deepak Gupta, Rafquat Rana, Aarti Abhishek Shah, Sonia Verma, Kothuri Naresh, Jiaur R Gayen, Manish K Chourasia
{"title":"通过 LC-MS/MS 同时估算紫杉醇和硼替佐米：制药和药代动力学应用。","authors":"Pavan K Yadav, Saurabh Verma, Divya Chauhan, Pooja Yadav, Amrendra K Tiwari, Ravi Saklani, Deepak Gupta, Rafquat Rana, Aarti Abhishek Shah, Sonia Verma, Kothuri Naresh, Jiaur R Gayen, Manish K Chourasia","doi":"10.1080/17435889.2024.2382668","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim & Objective:</b> This study evaluates the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy.<b>Materials & Methods:</b> The nanoformulation was optimized via Box-Behnken Design (BBD), with method validation adhering to US-FDA guidelines.<b>Results:</b> Multiple reaction monitoring transitions for PTX, BTZ and internal standard were m/z 855.80→286.60, 366.80→226.00 and 179.80→110.00, respectively. Elution done on C18 Luna column with 0.1% FA in MeOH:10 mM ammonium acetate. The size of nanoformulation was 133.9 ± 1.97 nm, PDI 0.19 ± 0.01 and zeta potential -19.20 ± 1.36 mV. Pharmacokinetics showed higher C<sub>max</sub> for PTX-BTZ-NE (313.75 ± 10.71 ng/ml PTX, 11.92 ± 0.53 ng/ml BTZ) versus free PTX-BTZ (104 ± 13.06 ng/ml PTX, 1.9 ± 0.08 ng/ml BTZ).<b>Conclusion:</b> Future findings will contribute to the treatment of breast cancer using PTX and BTZ.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485926/pdf/","citationCount":"0","resultStr":"{\"title\":\"Simultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applications.\",\"authors\":\"Pavan K Yadav, Saurabh Verma, Divya Chauhan, Pooja Yadav, Amrendra K Tiwari, Ravi Saklani, Deepak Gupta, Rafquat Rana, Aarti Abhishek Shah, Sonia Verma, Kothuri Naresh, Jiaur R Gayen, Manish K Chourasia\",\"doi\":\"10.1080/17435889.2024.2382668\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim & Objective:</b> This study evaluates the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy.<b>Materials & Methods:</b> The nanoformulation was optimized via Box-Behnken Design (BBD), with method validation adhering to US-FDA guidelines.<b>Results:</b> Multiple reaction monitoring transitions for PTX, BTZ and internal standard were m/z 855.80→286.60, 366.80→226.00 and 179.80→110.00, respectively. Elution done on C18 Luna column with 0.1% FA in MeOH:10 mM ammonium acetate. The size of nanoformulation was 133.9 ± 1.97 nm, PDI 0.19 ± 0.01 and zeta potential -19.20 ± 1.36 mV. Pharmacokinetics showed higher C<sub>max</sub> for PTX-BTZ-NE (313.75 ± 10.71 ng/ml PTX, 11.92 ± 0.53 ng/ml BTZ) versus free PTX-BTZ (104 ± 13.06 ng/ml PTX, 1.9 ± 0.08 ng/ml BTZ).<b>Conclusion:</b> Future findings will contribute to the treatment of breast cancer using PTX and BTZ.</p>\",\"PeriodicalId\":74240,\"journal\":{\"name\":\"Nanomedicine (London, England)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485926/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine (London, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17435889.2024.2382668\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2382668","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Simultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applications.
Aim & Objective: This study evaluates the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy.Materials & Methods: The nanoformulation was optimized via Box-Behnken Design (BBD), with method validation adhering to US-FDA guidelines.Results: Multiple reaction monitoring transitions for PTX, BTZ and internal standard were m/z 855.80→286.60, 366.80→226.00 and 179.80→110.00, respectively. Elution done on C18 Luna column with 0.1% FA in MeOH:10 mM ammonium acetate. The size of nanoformulation was 133.9 ± 1.97 nm, PDI 0.19 ± 0.01 and zeta potential -19.20 ± 1.36 mV. Pharmacokinetics showed higher Cmax for PTX-BTZ-NE (313.75 ± 10.71 ng/ml PTX, 11.92 ± 0.53 ng/ml BTZ) versus free PTX-BTZ (104 ± 13.06 ng/ml PTX, 1.9 ± 0.08 ng/ml BTZ).Conclusion: Future findings will contribute to the treatment of breast cancer using PTX and BTZ.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
